GF Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$178K Sell
1,266
-87
-6% -$12.4K ﹤0.01% 286
2026
Q2
$166K Sell
1,353
-51
-4% -$5.33K ﹤0.01% 291
2026
Q1
$148K Buy
1,404
+177
+14% +$15.7K ﹤0.01% 306
2025
Q4
$107K Sell
1,227
-111
-8% -$9.08K ﹤0.01% 339
2025
Q3
$88.9K Sell
1,338
-188
-12% -$10.7K ﹤0.01% 344
2025
Q2
$84.3K Hold
1,526
– – ﹤0.01% 381
2025
Q1
$73.8K Buy
1,526
+275
+22% +$11.5K ﹤0.01% 386
2024
Q4
$48.3K Buy
+1,251
New +$54.5K ﹤0.01% 392

Other funds holding PTGX

GF Fund Management's PTGX Position: Q3 2026 in Review

GF Fund Management reduced its Protagonist Therapeutics (PTGX) stake by 6.4% in Q3 2026, selling an estimated $12.4K and leaving 1,266 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #286.

GF Fund Management first reported a position in PTGX in Q4 2024 and has held it in 8 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • GF Fund Management held 1,266 shares of Protagonist Therapeutics worth $178K as of Q3 2026.
  • GF Fund Management sold 87 Protagonist Therapeutics shares in Q3 2026, an estimated $12.4K.
  • Protagonist Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #286 holding.
  • GF Fund Management first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.